Introduction <p>Mechanical thrombectomy (MT) efficacy in medium vessel occlusion (MeVO) stroke, particularly in patients with low Alberta Stroke Program Early Computed Tomography Score (ASPECTS), remains less explored.</p> Methods <p>This retrospective study analyzed data from 443 AIS patients treated with MT for MeVO and low ASPECTS (4–7) at 37 centers across North America, Asia, and Europe, from September 2017 to July 2021. Patients were categorized into ASPECTS of 4–5 and 6–7.</p> Results <p>Of 443 patients, 51 (12%) had ASPECTS of 4–5, and 392 (88%) had scores of 6–7. The median age was 65 years (IQR: 46–79), with a balanced sex distribution between the groups. The most common site of initial occlusion was M2 branch in both groups (92% in ASPECTS 4–5 and 85% in ASPECTS 6–7) (<i>p</i> = 0.68). The ASPECTS 4–5 group had lower TICI 2c-3 achievement (31% vs. 55%, <i>p</i> = 0.002) and poorer functional outcomes (mRS 0–1 at 90 days: 12% vs. 29%, <i>p</i> = 0.03) compared to the ASPECTS 6–7 group. Intracranial hemorrhagic complications were higher in the ASPECTS 4–5 group (69% vs. 47%, <i>p</i> = 0.007). Multivariable analysis revealed ASPECTS 6–7 to be associated with higher odds of TICI 2c-3 (OR: 2.5; CI: 1.28 to 4.89, <i>p</i> = 0.007) and lower odds of intracranial hemorrhagic complications (OR: 0.4; CI: 0.19 to 0.81, <i>p</i> = 0.012).</p> Conclusion <p>MT may be associated with improved outcomes in patients with moderate-to-low ASPECTS (6–7), though the lack of a control group limits definitive conclusions about its effectiveness. In patients with very low ASPECTS (4–5), higher rates of hemorrhagic complications and poorer outcomes were observed, but this does not necessarily preclude the use of MT. These findings highlight the need for further research and careful patient selection.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Outcomes of mechanical thrombectomy for medium vessel occlusion in acute ischemic stroke patients with ASPECTS 4–5 vs. 6–7: a retrospective, multicenter, and multinational study

  • Basel Musmar,
  • Hamza Adel Salim,
  • Nimer Adeeb,
  • Vivek Yedavalli,
  • Dhairya Lakhani,
  • Kareem El Naamani,
  • Nils Henninger,
  • Sri Hari Sundararajan,
  • Anna Luisa Kühn,
  • Jane Khalife,
  • Sherief Ghozy,
  • Luca Scarcia,
  • Benjamin Y. Q. Tan,
  • Robert W. Regenhardt,
  • Jeremy J. Heit,
  • Nicole M. Cancelliere,
  • Joshua D. Bernstock,
  • Aymeric Rouchaud,
  • Jens Fiehler,
  • Sunil Sheth,
  • Ajit S. Puri,
  • Christian Dyzmann,
  • Marco Colasurdo,
  • Xavier Barreau,
  • Leonardo Renieri,
  • João Pedro Filipe,
  • Pablo Harker,
  • Răzvan Alexandru Radu,
  • Mohamad Abdalkader,
  • Piers Klein,
  • Thomas R. Marotta,
  • Julian Spears,
  • Takahiro Ota,
  • Ashkan Mowla,
  • Pascal Jabbour,
  • Arundhati Biswas,
  • Frédéric Clarençon,
  • James E. Siegler,
  • Thanh N. Nguyen,
  • Ricardo Varela,
  • Amanda Baker,
  • Muhammed Amir Essibayi,
  • David Altschul,
  • Nestor R. Gonzalez,
  • Markus A. Möhlenbruch,
  • Vincent Costalat,
  • Benjamin Gory,
  • Christian Paul Stracke,
  • Mohammad Ali Aziz-Sultan,
  • Constantin Hecker,
  • Hamza Shaikh,
  • David S. Liebeskind,
  • Alessandro Pedicelli,
  • Andrea M. Alexandre,
  • Illario Tancredi,
  • Tobias D. Faizy,
  • Erwah Kalsoum,
  • Boris Lubicz,
  • Aman B. Patel,
  • Vitor Mendes Pereira,
  • Adrien Guenego,
  • Adam A. Dmytriw,
  • Abdelaziz Amllay,
  • Achala Vagal,
  • Adrien ter Schiphorst,
  • Ajith J. Thomas,
  • Anil Gopinathan,
  • Anne Dusart,
  • Carolina Capirossi,
  • Charbel Mounayer,
  • Charlotte Weyland,
  • Cheng-Yang Hsieh,
  • Christoph J. Griessenauer,
  • Christopher J. Stapleton,
  • Flavio Bellante,
  • Gaultier Marnat,
  • Géraud Forestier,
  • Hugo H. Cuellar-Saenz,
  • Iacopo Valente,
  • Igor Sibon,
  • James D. Rabinov,
  • Jérôme Berge,
  • Jessica Jesser,
  • Juan Carlos Martinez-Gutierrez,
  • Kevin Premat,
  • Leonard LL. Yeo,
  • Lina Chervak,
  • Lukas Meyer,
  • Mahmoud Elhorany,
  • Miguel Quintero-Consuegra

摘要

Introduction

Mechanical thrombectomy (MT) efficacy in medium vessel occlusion (MeVO) stroke, particularly in patients with low Alberta Stroke Program Early Computed Tomography Score (ASPECTS), remains less explored.

Methods

This retrospective study analyzed data from 443 AIS patients treated with MT for MeVO and low ASPECTS (4–7) at 37 centers across North America, Asia, and Europe, from September 2017 to July 2021. Patients were categorized into ASPECTS of 4–5 and 6–7.

Results

Of 443 patients, 51 (12%) had ASPECTS of 4–5, and 392 (88%) had scores of 6–7. The median age was 65 years (IQR: 46–79), with a balanced sex distribution between the groups. The most common site of initial occlusion was M2 branch in both groups (92% in ASPECTS 4–5 and 85% in ASPECTS 6–7) (p = 0.68). The ASPECTS 4–5 group had lower TICI 2c-3 achievement (31% vs. 55%, p = 0.002) and poorer functional outcomes (mRS 0–1 at 90 days: 12% vs. 29%, p = 0.03) compared to the ASPECTS 6–7 group. Intracranial hemorrhagic complications were higher in the ASPECTS 4–5 group (69% vs. 47%, p = 0.007). Multivariable analysis revealed ASPECTS 6–7 to be associated with higher odds of TICI 2c-3 (OR: 2.5; CI: 1.28 to 4.89, p = 0.007) and lower odds of intracranial hemorrhagic complications (OR: 0.4; CI: 0.19 to 0.81, p = 0.012).

Conclusion

MT may be associated with improved outcomes in patients with moderate-to-low ASPECTS (6–7), though the lack of a control group limits definitive conclusions about its effectiveness. In patients with very low ASPECTS (4–5), higher rates of hemorrhagic complications and poorer outcomes were observed, but this does not necessarily preclude the use of MT. These findings highlight the need for further research and careful patient selection.